ORLANDO — In this video, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses preclinical data on vorolanib presented at Eyecelerator@AAO.
“We’ve always known that vorolanib was a potent inhibitor of all the VEGF receptors,” Duker said. “What we’ve now discovered is we also have an anti-inflammatory component to vorolanib.”
Duker explained that “with this essentially bispecific approach of blocking both VEGF and inflammation, we are especially confident in the results of our clinical trial.”